Dans le cadre du mois de sensibilisation au cancer colorectal, lisez cet article fort intéressant avec la participation de notre chercheur membre Dr Mustapha Tehfe: lactualite.com/actualites/le-…

Un casse-tête administratif prive le Bas-Saint-Laurent d’un neurologue | Radio-Canada.ca ⁦ ici.radio-canada.ca/nouvelle/19602…

Dans ma note KEYNOTE rendu qui notent #MedTwitter

#Quebec #AMHOQ

Notre #President #AMHOQ

Thank you Dr.Christine Simmons for you presentation of breast cancer at #AMHOQ and specially your effort for the french language

😢 J’ai vu plusieurs films, il est un icone!!

Seems we are all checking ASCO #asco23 program Frozen!!!

#ASCO23 I prescribe A LOT of capecitabine for #GIcancers and HFS is a big problem 😓 👇topical diclofenac to the rescue? D-TORCH randomized, placebo-controlled study 🇮🇳 📌 n=263 📌 4-fold ⬇️ in grade 2+ cape HFS! ⭐️ practice-changing 👏 meetings.asco.org/abstracts-pres…

Awesome work from our team CHUM piloted by #FrancisProulxRocray : The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and the... sciencedirect.com/science/articl… @tehfem @BertrandRouty Marion Tonneau Rami Nassabein

Nouveau défi!!!! CISSS du Bas-Saint-Laurent

A study that was enrolling at Rimouski CISSS du Bas-Saint-Laurent

Agent ou agente de planification, de programmation et de recherche | Centre intégré de santé et de services sociaux du Bas-Saint-Laurent postuler.cisssbsl.com/CL3/xweb/xweb.…

Les hémato-oncologues du #Québec #AMHOQ

Running vs. Antidepressant (SSRI) for Depression/Anxiety: -Similar remission rates (45% vs 43%) over 16 weeks -Compared to SSRIs, the running group had ⬇️ weight, waist circumference, and blood pressure 1/12

🔥🚨OncoAlert Hot off the press. Just published NEJM in conjunction with #PLENARY presentation ASCO #ASCO24 PRACTICE CHANGING #LAURA trial of consolidation #Osimertinib after concurrent chemoradiation in stage III #EGFR+ Non–Small Cell #LungCancer 👇🏼 nejm.org/doi/full/10.10…

#ESMO24 @tehfem Canadian prespective of CM649

ADCs combine the potency of chemo with the PK of mAbs. This translates into increased antitumor activity, but also in delayed toxicities. The most common, with T-DXd: nausea. Check this interesting Annals of Oncology editorial on the ERICA randomized trial. annalsofoncology.org/article/S0923-…

Ce que j’apprends en congrès 🥲 #ASCO25